The research question is adequate and the methods are clearly reported. The authors use the term "untargeted" antifungal treatment to described all the antifungal strategies adopted before definitive diagnosis of IFI. The first reference to use this term and to study these strategies all together is the 2016 Cochrane review from Cortegiani et al. Although it sounds, the authors should note that this definition (untargeted antifungal treatment) was criticized after the publication of the review and other related papers. So, I suggest to describe what is the advantage for clinicians to evaluate these strategies all together instead of separately. In my opinion, in clinical practice is often difficult to know kind of antifungal strategies one is using, depending on patients' characteristics, risk factors, infections. In this way, the intervention is studies as a whole. Pag. 3 Limitations: the authors should add that the intervention under investigations include different strategies (prophylaxis, preemptive, empiric treatment) and this may lead to clinical heterogeneity. So not only the trials but also the interventions will be heterogenous. Pag. 4 line 42-43: References 6 and 7 are not adequate to describe the definition of untargeted antifungal treatment. Not Playford et al. nor ESCMID guidelines used this term and concept. I provide here some reference other than the Cochrane review for further information for the readers (doi: 10.1186 /s13054-016-1284 10.5152/TJAR.2016.0010 ; 10.1016 /j.ejim.2016 . In my opinion, authors should delete reference 6 and 7 in these lines and replace them. Pag. 5 Line 25-26: when referring to reviews for the Cochrane Collaboration, authors should use the term "Cochrane review" Pag. 7 Line 5-6: Authors should describe what time measure of the outcome "mortality" they would prefer when many time measure would be available (e.g. ICU mortality, end-of-treatment mortality, etc.) I also suggest the authors to better specify if they plan to enroll both neutropenic and non-neutropenic patients. This is crucial because the effect of the intervention varies widely among neutropenic and non neutropenic patients.
The statistical plan and the methods of the systematic review is adequate and well reported.
REVIEWER
A/Professor Jennifer Paratz University of Queensland, Brisbane, Australia REVIEW RETURNED 25-Feb-2017 GENERAL COMMENTS Excellent protocol. All aspects of designing a systematic review are covered. The subject matter is important and a new review is warranted, as this proposed review covers important outcomes to patients
VERSION 1 -AUTHOR RESPONSE
Comments from reviewer#1
1. The research question is adequate and the methods are clearly reported.
Thank you.
2. The reviewer points out issues with the term and definition "untargeted antifungal therapy". The reviewer suggests describing the advantages of evaluating these strategies all together instead of separately.
This has been added to the revised manuscript (page 5).
3. The reviewer considers the different intervention strategies as a limitation to this study as it may lead to clinical heterogeneity.
We agree, and have acknowledged this as a limitation in the revised manuscript (page 3). Of note, a subgroup analysis comparing the different untargeted therapies is planned (page 9).
4. The reviewer states that reference 6 and 7 are not adequate to describe the definition of untargeted antifungal therapy. The reviewer provides other relevant references.
Thank you for providing these relevant references, which we have included in the revised manuscript (page 4-5).
5. The reviewer request to use the term "Cochrane review" rather than "review" when referring to reviews from the Cochrane Collaboration.
6. The reviewer request a description of the preferred time measure of the outcome "mortality" when multiple time measures are available.
The primary outcome measure is all-cause short-term mortality, defined as ≤ 90 days, including in-ICU and in-hospital mortality. We deem that this definition will favour our protocol and review compared to being limited to one or several specific time point as this would likely reduce the number of eligible trials and thereby weaken the results. If multiple time points ≤ 90 days are reported, we will use and report the outcome with the longest follow-up. For the secondary outcomes, including longterm mortality (>90 days) the same strategy will be used. This has been highlighted in the revised manuscript (page 7).
7. The reviewer suggests specifying if both trials conducted in neutropenic and non-neutropenic patients will be enrolled in the review.
We intend to enroll neutropenic as well as non-neutropenic patients. This has been added to the revised manuscript (page 6). As these two entities may differ, a subgroup analysis comparing estimates in the two groups have been added to the revised manuscript (page 10).
Comments from reviewer#2
1. Excellent protocol. All aspects of designing a systematic review are covered. The subject matter is important and a new review is warranted, as this proposed review covers important outcomes to patients.
Thank you again for considering our paper for publication in BMJ Open.
VERSION 2 -REVIEW

REVIEWER
Andrea Cortegiani Policlinico P. Giaccone. University of Palermo, Italy.
REVIEW RETURNED
10-Mar-2017
GENERAL COMMENTS
Thank you for considering me to review this revised paper. Thank you for revising the manuscript according to our suggestions. I have no queries.
